Renin-angiotensin-aldosterone system related gene polymorphisms and urinary total arsenic is related to chronic kidney disease

Toxicology and Applied Pharmacology

Volumn 279, Issue 2, 2014, Pages 95-102

  Chen, Wei Jen ^a   Huang, Ya Li ^b   Shiue, Horng Sheng ^c   Chen, Tzen Wen ^b,d   Lin, Yuh Feng ^e,f   Huang, Chao Yuan ^g   Lin, Ying Chin ^b,f,h   Han, Bor Cheng ^a   Hsueh, Yu Mei ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^h TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Aldosterone synthase (CYP11B2); Angiotensinogen (AGT); Arsenic; Chronic kidney disease; Gene polymorphisms; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE SYNTHASE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; ARSENIC; DIPEPTIDYL CARBOXYPEPTIDASE;

AGED; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME REGULATION; FEMALE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; QUESTIONNAIRE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; URINARY TOTAL ARSENIC LEVEL; URINE LEVEL;

ALDOSTERONE SYNTHASE (CYP11B2); ANGIOTENSINOGEN (AGT); ARSENIC; CHRONIC KIDNEY DISEASE; GENE POLYMORPHISMS; RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM;

AGED; ALDOSTERONE SYNTHASE; ANGIOTENSINOGEN; ARSENIC; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PEPTIDYL-DIPEPTIDASE A; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTOR, ANGIOTENSIN, TYPE 1; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; RISK FACTORS; SPECTROPHOTOMETRY, ATOMIC; TAIWAN;

EID: 84903728128     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.05.011     Document Type: Article

References (54)

1. Anbazhagan K., Sampathkumar K., Ramakrishnan M., Gomathi P., Gomathi S., Selvam G.S. Analysis of polymorphism in renin angiotensin system and other related genes in South Indian chronic kidney disease patients. Clin. Chim. Acta 2009, 406:108-112.
2. Andersson B., Blange I., Sylven C. Angiotensin-II type 1 receptor gene polymorphism and long-term survival in patients with idiopathic congestive heart failure. Eur. J. Heart Fail. 1999, 1:363-369.
3. Bantis C., Heering P.J., Stangou M., Kouri N.M., Schwandt C., Memmos D., Rump L.C., Ivens K. Influence of aldosterone synthase gene C-344T polymorphism on focal segmental glomerulosclerosis. Nephrology (Carlton) 2011, 16:730-735.
4. Bassett M.H., Zhang Y., Clyne C., White P.C., Rainey W.E. Differential regulation of aldosterone synthase and 11beta-hydroxylase transcription by steroidogenic factor-1. J. Mol. Endocrinol. 2002, 28:125-135.
5. Brand E., Chatelain N., Paillard F., Tiret L., Visvikis S., Lathrop M., Soubrier F., Demenais F. Detection of putative functional angiotensinogen (AGT) gene variants controlling plasma AGT levels by combined segregation-linkage analysis. Eur. J. Hum. Genet. 2002, 10:715-723.
6. Brewster U.C., Perazella M.A. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am. J. Med. 2004, 116:263-272.
7. Cameron V.A., Mocatta T.J., Pilbrow A.P., Frampton C.M., Troughton R.W., Richards A.M., Winterbourn C.C. Angiotensin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure. Hypertension 2006, 47:1155-1161.
8. Chen Y.C., Amarasiriwardena C.J., Hsueh Y.M., Christiani D.C. Stability of arsenic species and insoluble arsenic in human urine. Cancer Epidemiol. Biomarkers Prev. 2002, 11:1427-1433.
9. Chen J.W., Chen H.Y., Li W.F., Liou S.H., Chen C.J., Wu J.H., Wang S.L. The association between total urinary arsenic concentration and renal dysfunction in a community-based population from central Taiwan. Chemosphere 2011, 84:17-24.
10. Chen Y., Parvez F., Liu M., Pesola G.R., Gamble M.V., Slavkovich V., Islam T., Ahmed A., Hasan R., Graziano J.H., Ahsan H. Association between arsenic exposure from drinking water and proteinuria: results from the Health Effects of Arsenic Longitudinal Study. Int. J. Epidemiol. 2011, 40:828-835.
11. Chiou J.M., Wang S.L., Chen C.J., Deng C.R., Lin W., Tai T.Y. Arsenic ingestion and increased microvascular disease risk: observations from the south-western arseniasis-endemic area in Taiwan. Int. J. Epidemiol. 2005, 34:936-943.
12. Chung C.J., Huang Y.L., Huang Y.K., Wu M.M., Chen S.Y., Hsueh Y.M., Chen C.J. Urinary arsenic profiles and the risks of cancer mortality: a population-based 20-year follow-up study in arseniasis-endemic areas in Taiwan. Environ. Res. 2013, 122:25-30.
13. Cooper Worobey C., Fisher N.D., Cox D., Forman J.P., Curhan G.C. Genetic polymorphisms and the risk of accelerated renal function decline in women. PLoS One 2009, 4:e4787.
14. Dickson M.E., Tian X., Liu X., Davis D.R., Sigmund C.D. Upstream stimulatory factor is required for human angiotensinogen expression and differential regulation by the A-20C polymorphism. Circ. Res. 2008, 103:940-947.
15. Fabris B., Bortoletto M., Candido R., Barbone F., Cattin M.R., Calci M., Scanferla F., Tizzoni L., Giacca M., Carretta R. Genetic polymorphisms of the renin-angiotensin-aldosterone system and renal insufficiency in essential hypertension. J. Hypertens. 2005, 23:309-316.
16. Hsueh Y.M., Huang Y.L., Huang C.C., Wu W.L., Chen H.M., Yang M.H., Lue L.C., Chen C.J. Urinary levels of inorganic and organic arsenic metabolites among residents in an arseniasis-hyperendemic area in Taiwan. J. Toxicol. Environ. Health A 1998, 54:431-444.
17. Hsueh Y.-M., Chung C.-J., Shiue H.-S., Chen J.-B., Chiang S.-S., Yang M.-H., Tai C.-W., Su C.-T. Urinary arsenic species and CKD in a Taiwanese population: a case-control study. Am. J. Kidney Dis. 2009, 54:859-870.
18. Iseki K., Ikemiya Y., Iseki C., Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003, 63:1468-1474.
19. Jones M.R., Tellez-Plaza M., Sharrett A.R., Guallar E., Navas-Acien A. Urine arsenic and hypertension in US adults: the 2003-2008 National Health and Nutrition Examination Survey. Epidemiology 2011, 22:153-161.
20. KDOQI K.D.O.Q.I. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 2002, 39:S1-S266.
21. Kim Y., Lee B.K. Association between urinary arsenic and diabetes mellitus in the Korean general population according to KNHANES 2008. Sci. Total Environ. 2011, 409:4054-4062.
22. Ko G.J., Kang Y.S., Lee M.H., Song H.K., Kim H.K., Cha D.R. Polymorphism of the aldosterone synthase gene is not associated with progression of diabetic nephropathy, but associated with hypertension in type 2 diabetic patients. Nephrology (Carlton) 2008, 13:492-499.
23. Kuo H.-W., Tsai S.-S., Tiao M.-M., Liu Y.-C., Lee I.M., Yang C.-Y. Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol. Drug Saf. 2010, 19:745-751.
24. Kupari M., Hautanen A., Lankinen L., Koskinen P., Virolainen J., Nikkila H., White P.C. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 1998, 97:569-575.
25. Lee J.E., Bae S.Y., Kim J.Y., Pyo H.J., Kwon Y.J. Aldosterone synthase gene (CYP11B2) polymorphism in Korean end-stage renal disease patients on hemodialysis. Electrolyte Blood Press. 2009, 7:67-72.
26. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 1999, 130:461-470.
27. Lindpaintner K., Pfeffer M.A., Kreutz R., Stampfer M.J., Grodstein F., LaMotte F., Buring J., Hennekens C.H. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N. Engl. J. Med. 1995, 332:706-711.
28. Maeda S. Genetics of diabetic nephropathy. Ther. Adv. Cardiovasc. Dis. 2008, 2:363-371.
29. Meliker J.R., Wahl R.L., Cameron L.L., Nriagu J.O. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: a standardized mortality ratio analysis. Environ. Health 2007, 6:4.
30. Nistala R., Wei Y., Sowers J.R., Whaley-Connell A. Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney disease. Transl. Res. 2009, 153:102-113.
31. Niu T., Yang J., Wang B., Chen W., Wang Z., Laird N., Wei E., Fang Z., Lindpaintner K., Rogus J.J., Xu X. Angiotensinogen gene polymorphisms M235T/T174M: no excess transmission to hypertensive Chinese. Hypertension 1999, 33:698-702.
32. Ott C., Schwarz T., Hilgers K.F., Kreutz R., Schlaich M.P., Schmieder R.E. Left-ventricular structure and function are influenced by angiotensinogen gene polymorphism (-20 A/C) in young male patients. Am. J. Hypertens. 2007, 20:974-980.
33. Padro-Miquel A., Alia-Ramos P., Gonzalez-Alvarez M.T., Navarro-Moreno M.A. Survival in type 2 diabetic patients in dialysis and the number of risk alleles in polymorphisms of the renin-angiotensin system genes. Clin. Biochem. 2009, 42:5-11.
34. Paul M., Poyan Mehr A., Kreutz R. Physiology of local renin-angiotensin systems. Physiol. Rev. 2006, 86:747-803.
35. Pereira T.V., Nunes A.C., Rudnicki M., Yamada Y., Pereira A.C., Krieger J.E. Meta-analysis of the association of 4 angiotensinogen polymorphisms with essential hypertension: a role beyond M235T?. Hypertension 2008, 51:778-783.
36. Sachse A., Wolf G. Angiotensin II-induced reactive oxygen species and the kidney. J. Am. Soc. Nephrol. 2007, 18:2439-2446.
37. San Jose G., Fortuno A., Moreno M.U., Robador P.A., Bidegain J., Varo N., Beloqui O., Diez J., Zalba G. The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: potential implication in hypertension. Clin. Sci. (Lond.) 2009, 116:233-240.
38. Sarzani R., Bordicchia M., Marcucci P., Minardi D., Muzzonigro G., Dessi-Fulgheri P., Rappelli A. Angiotensinogen promoter variants influence gene expression in human kidney and visceral adipose tissue. J. Hum. Hypertens. 2010, 24:213-219.
39. Sethi A.A., Nordestgaard B.G., Tybjaerg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1269-1275.
40. Siragy H.M., Carey R.M. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am. J. Nephrol. 2010, 31:541-550.
41. Soderland P., Lovekar S., Weiner D.E., Brooks D.R., Kaufman J.S. Chronic kidney disease associated with environmental toxins and exposures. Adv. Chronic Kidney Dis. 2010, 17:254-264.
42. Su S.L., Lu K.C., Lin Y.F., Hsu Y.J., Lee P.Y., Yang H.Y., Kao S.Y. Gene polymorphisms of angiotensin-converting enzyme and angiotensin II Type 1 receptor among chronic kidney disease patients in a Chinese population. J Renin-Angiotensin-Aldosterone Syst 2012, 13:148-154.
43. Tien K.J., Hsiao J.Y., Hsu S.C., Liang H.T., Lin S.R., Chen H.C., Hsieh M.C. Gender-dependent effect of ACE I/D and AGT M235T polymorphisms on the progression of urinary albumin excretion in Taiwanese with type 2 diabetes. Am. J. Nephrol. 2009, 29:299-308.
44. Tseng C.H. The potential biological mechanisms of arsenic-induced diabetes mellitus. Toxicol. Appl. Pharmacol. 2004, 197:67-83.
45. USEPA Fact Sheet about the January 2001 Arsenic Rule (EPA 815-F-00-015) 2001, US Environmental Protection Agency, (http://water.epa.gov/lawsregs/rulesregs/sdwa/arsenic/regulations_factsheet.cfm).
46. Vahter M. Mechanisms of arsenic biotransformation. Toxicology 2002, 181-182:211-217.
47. Walton F.S., Harmon A.W., Paul D.S., Drobna Z., Patel Y.M., Styblo M. Inhibition of insulin-dependent glucose uptake by trivalent arsenicals: possible mechanism of arsenic-induced diabetes. Toxicol. Appl. Pharmacol. 2004, 198:424-433.
48. Wang J.P., Wang S.L., Lin Q., Zhang L., Huang D., Ng J.C. Association of arsenic and kidney dysfunction in people with diabetes and validation of its effects in rats. Environ. Int. 2009, 35:507-511.
49. Weiner D.E., Tighiouart H., Amin M.G., Stark P.C., MacLeod B., Griffith J.L., Salem D.N., Levey A.S., Sarnak M.J. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J. Am. Soc. Nephrol. 2004, 15:1307-1315.
50. Wen C.P., Cheng T.Y.D., Tsai M.K., Chang Y.C., Chan H.T., Tsai S.P., Chiang P.H., Hsu C.C., Sung P.K., Hsu Y.H., Wen S.F. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462,293 adults in Taiwan. Lancet 2008, 371:2173-2182.
51. White P.C., Slutsker L. Haplotype analysis of CYP11B2. Environ. Res. 1995, 21:437-442.
52. WHO Guidelines for drinking water quality 2011, Fourth ed.
53. Wu M.M., Chiou H.Y., Hsueh Y.M., Hong C.T., Su C.L., Chang S.F., Huang W.L., Wang H.T., Wang Y.H., Hsieh Y.C., Chen C.J. Effect of plasma homocysteine level and urinary monomethylarsonic acid on the risk of arsenic-associated carotid atherosclerosis. Toxicol. Appl. Pharmacol. 2006, 216:168-175.
54. Yamagata K., Ishida K., Sairenchi T., Takahashi H., Ohba S., Shiigai T., Narita M., Koyama A. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007, 71:159-166.